TachoSil sealant matrix European Union - English - myHealthbox

tachosil sealant matrix

takeda austria gmbh - human fibrinogen / human thrombin - sealant matrix - 5.5 mg human fibrinogen and 2.0 iu human thrombin per cm² - hemostasis, surgical - local haemostatics - indicated in adults for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing, and for suture support in vascular surgery where standard techniques are insufficient

PANTOPRAZOLE NYCOMED Ireland - English - HPRA (Health Products Regulatory Authority)

pantoprazole nycomed

nycomed gmbh - pantoprazole - tablets gastro-resistant - 20 milligram

PANTOPRAZOLE NYCOMED Ireland - English - HPRA (Health Products Regulatory Authority)

pantoprazole nycomed

nycomed gmbh - pantoprazole - tablets gastro-resistant - 40 milligram

PANTOPRAZOLE NYCOMED I.V. Ireland - English - HPRA (Health Products Regulatory Authority)

pantoprazole nycomed i.v.

nycomed gmbh - pantoprazole - pdr for soln for injection - 40 milligram

PROAMATINE- midodrine hydrochloride tablet United States - English - NLM (National Library of Medicine)

proamatine- midodrine hydrochloride tablet

physicians total care, inc. - midodrine hydrochloride (unii: 59jv96ytxv) (midodrine - unii:6ye7pbm15h) - midodrine hydrochloride 5 mg - proamatine ® is indicated for the treatment of symptomatic orthostatic hypotension (oh). because proamatine ® can cause marked elevation of supine blood pressure (bp>200 mmhg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. the indication is based on proamatine ® 's effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. at present, however, clinical benefits of proamatine ® , principally improved ability to perform life activities, have not been established. further clinical trials are underway to verify and describe the clinical benefits of proamatine ® . after initiation of treatment, proamatine ® should be continued only for patients who report significant symptomatic improvement. proamatine ® is contraindicated in patients with severe

CONTROLOC 40mg I.V.vial Egypt - English - EDA (Egyptian Drug Authority)

controloc 40mg i.v.vial

nycomed scientific office-egypt - injection - 40 mg